ACAD
34.33
+0.5
+1.48%
AEMD
2.23
-0.04
-1.76%
APRI
1.13
+0.02
+1.80%
ARNA
1.34
-0.04
-2.90%
ATEC
2.03
-0.1
-4.69%
CNAT
8.36
-0.41
-4.68%
CRXM
0.195
+0.012
+6.47541%
CYTX
1.03
-0.04
-3.74%
DXCM
77.96
+0.03
+0.04%
GNMK
12.82
-0.06
-0.47%
HALO
13.94
-0.05
-0.36%
ILMN
184.86
+1.12
+0.61%
INNV
0.09
0.00
-1.10%
INO
6.29
-0.14
-2.18%
ISCO
1.75
+0.08
+4.48%
ISIS
57.56
0.00
0.00%
LGND
111.17
-0.02
-0.02%
LPTN
2.93
-0.08
-2.66%
MBVX
2.27
+0.06
+2.71%
MEIP
1.59
0.00
0.00%
MNOV
5.75
-0.07
-1.20%
MRTX
4.55
-0.22
-4.71%
MSTX
0.131
-0.007
-5.278%
NBIX
53.4
-0.19
-0.35%
NUVA
72.51
-0.3
-0.41%
ONCS
1.15
+0.01
+0.88%
ONVO
2.9
+0.01
+0.35%
OREX
3.37
-0.24
-6.65%
OTIC
13.35
-0.3
-2.20%
QDEL
24.17
+0.02
+0.08%
RCPT
231.96
0.00
0.00%
RGLS
1.55
-0.05
-3.13%
RMD
67.99
-4.86
-6.67%
SPHS
2.578
+0.028
+1.0863%
SRNE
1.95
-0.15
-7.14%
TROV
0.93
+0.02
+2.46%
VICL
2.36
+0.05
+2.16%
VOLC
18
0.00
0.00%
ZGNX
11
0.00
0.00%
ACAD
34.33
+0.5
+1.48%
AEMD
2.23
-0.04
-1.76%
APRI
1.13
+0.02
+1.80%
ARNA
1.34
-0.04
-2.90%
ATEC
2.03
-0.1
-4.69%
CNAT
8.36
-0.41
-4.68%
CRXM
0.195
+0.012
+6.47541%
CYTX
1.03
-0.04
-3.74%
DXCM
77.96
+0.03
+0.04%
GNMK
12.82
-0.06
-0.47%
HALO
13.94
-0.05
-0.36%
ILMN
184.86
+1.12
+0.61%
INNV
0.09
0.00
-1.10%
INO
6.29
-0.14
-2.18%
ISCO
1.75
+0.08
+4.48%
ISIS
57.56
0.00
0.00%
LGND
111.17
-0.02
-0.02%
LPTN
2.93
-0.08
-2.66%
MBVX
2.27
+0.06
+2.71%
MEIP
1.59
0.00
0.00%
MNOV
5.75
-0.07
-1.20%
MRTX
4.55
-0.22
-4.71%
MSTX
0.131
-0.007
-5.278%
NBIX
53.4
-0.19
-0.35%
NUVA
72.51
-0.3
-0.41%
ONCS
1.15
+0.01
+0.88%
ONVO
2.9
+0.01
+0.35%
OREX
3.37
-0.24
-6.65%
OTIC
13.35
-0.3
-2.20%
QDEL
24.17
+0.02
+0.08%
RCPT
231.96
0.00
0.00%
RGLS
1.55
-0.05
-3.13%
RMD
67.99
-4.86
-6.67%
SPHS
2.578
+0.028
+1.0863%
SRNE
1.95
-0.15
-7.14%
TROV
0.93
+0.02
+2.46%
VICL
2.36
+0.05
+2.16%
VOLC
18
0.00
0.00%
ZGNX
11
0.00
0.00%
Home » Hugo Villar, Ph.D., MBA-Bio

Hugo Villar, Ph.D., MBA-Bio

Hugo O. Villar Ph.D., MBA is director for Science and Technology programs at UC San Diego Extension. He is also President of Altoris, Inc. a San Diego based specializing in information management for the biotech and pharmaceutical industries and providing consulting on discovery technologies. He was Vice President for Chemoproteomics at Triad Therapeutics and Vice President of Discovery Technologies at Telik, Inc. His work resulted in over 80 publications and 18 patents on the development of technologies for drug discovery. He has a Ph.D. in Chemistry and an MBA with a concentration in Pharmaceuticals and Helathcare.

Be Sociable, Share!